Leadership
How hiring the best leaders maximizes biotech exit values
We’ve seen some major exits in the biotech market in 2017. Early in the year, in Switzerland alone, Actelion was sold to Johnson &...
Engaging with executive interims – time for a fresh perspective
Habits are hard to break and all too often we return to established patterns of behaviour rather than looking for innovative ways to do...
Diversity: A call to arms for Biotech Leaders and Investors
A panel discussion, led by The RSA Group, at the recent BIA UK CEO & Investor Forum discussed the demographic time bomb facing biotech boards...
Building talent and saving lives
London was the setting last week for the 25th Annual Meeting of the International Society for Cellular Therapy. The huge increase of clinical trials...
Behavioural profiling in the search for medical affairs professionals
In pharmaceutical companies, medical affairs professionals play a vital yet complex role: acting as a bridge between the medical and commercial groups, and as...
A report from the 2018 J.P.Morgan Healthcare Conference
A quiet JPM18? I don’t think so. One thing I learned at JPM18 was that journalists see the world differently to me. There were...
Talent equity is the long term value of biotech
Valuation of IP is familiar to every investor in the biotech sector and careful due diligence is essential before putting money at risk. We...
Hiring new talent – it pays to be diligent
Companies hire new senior talent to fuel corporate success. Too often it proves to be an expensive failure. New data from Leadership IQ1 across...